Loading market dashboard
Paratek Pharmaceuticals, Inc.
PRTKHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Highlights include pooled safety findings from Paratek's Phase 3 studies in community acquired pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), as well as additional clinical and non-clinical data from Company- and investigator-sponsored studies KING OF PRUSSIA, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic areas, today announced that new data from scientific and investigator-initiated studies of NUZYRA® (omadacycline) will be presented at ESCMID Global 2026, the annual Congress of the European Society of Clinical Microbiology and Infectious Diseases, taking place in Munich, Germany, April 17-21.
Transaction adds TYMLOS ® to portfolio alongside NUZYRA ® and XHANCE ® and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026 KING OF PRUSSIA, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic areas, today announced the completion of its combination with Radius Health, Inc., adding the osteoporosis therapy TYMLOS® (abaloparatide) to its growing commercial portfolio of differentiated specialty medicines.
